Another key factor contributing to SCLC drug resistance is the expression of CD133, a stem cell marker that is associated with increased expression of BCL-2 and p-glycoprotein (P-gp), both of which are involved in resistance to chemotherapy [138]. Here, BCL2 is linked to small cell lung carcinoma.